Indeed, combination treatment with a CDC7 inhibitor and oxaliplatin achieved a strong synergistic effect in vitro and in vivo, suggesting the potential clinical value of a CDC7 inhibitor in CRC. This evidence concerns the gene CDC7 and colorectal carcinoma.